BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       

«Kaken Pharmaceutical Co Limited

Below is an extended Kaken Pharmaceutical Co Limited research listing. Click here to return to the Kaken Pharmaceutical Co Limited main Biocorporate entry.

Recent Publications by Kaken Pharmaceutical Co Limited:

Effects of KP-496, a novel dual antagonist at the cysteinyl leukotriene receptor 1 and the thromboxane A(2) receptor, on airway obstruction in guinea pigs.
BACKGROUND AND PURPOSE: KP-496 is a novel dual antagonist for cysteinyl...
15th May, 2008
Pharmacology Department, Central Research Laboratories, Kaken Br J Pharmacol. 2008 Feb;153(4):669-75. Epub 2007 Nov 26.
DOI Direct Link
Preparation of rapidly disintegrating tablets containing itraconazole solid dispersions.
The disintegratability of tablets prepared from two types of solid...
6th February, 2008
Drug Formulation Department, Central Research Laboratories, Kaken Chem Pharm Bull (Tokyo). 2007 Nov;55(11):1557-62.
Fibroblast growth factor-2-induced host stroma reaction during initial tumor growth promotes progression of mouse melanoma via vascular endothelial growth factor A-dependent neovascularization.
Fibroblast growth factor (FGF)-2 has been considered to play a critical...
3rd May, 2007
Safety Research Department, Central Research Laboratories, Kaken Cancer Sci. 2007 Apr;98(4):541-8. Epub 2007 Mar 14.
DOI Direct Link
Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea.
BACKGROUND: A dry powder inhaler of KP-496 is currently in clinical...
4th April, 2007
Pharmacology Department, Central Research Laboratories, Kaken Allergol Int. 2006 Dec;55(4):403-10.
DOI Direct Link
KP-102 (growth hormone-releasing peptide-2) attenuates ischemia/reperfusion injury in isolated rat hearts.
KP-102, a synthetic growth hormone (GH)-releasing peptide, exerts a...
29th March, 2007
Pharmacology Department, Central Research Laboratories, Kaken Naunyn Schmiedebergs Arch Pharmacol. 2006 Aug;373(5):360-6. Epub 2006 Jun
DOI Direct Link
F2928-1 and -2, new antifungal antibiotics from Cladobotryum sp.
Two new antifungal antibiotics, F2928-1 (1) and -2 (2), were isolated from...
22nd December, 2005
Research Laboratory Agrochemical & Animal Health Products Department, J Antibiot (Tokyo). 2005 Aug;58(8):507-13.
ACTH releasing activity of KP-102 (GHRP-2) in rats is mediated mainly by release of CRF.
KP-102 (GHRP-2: pralmorelin) is a synthetic growth hormone releasing...
12th July, 2005
Central Research Laboratories, Kaken Pharmaceutical Co. Ltd., 14 Shinomiya Naunyn Schmiedebergs Arch Pharmacol. 2005 Jan;371(1):54-60. Epub 2005 Jan
DOI Direct Link
2,3-Diphenylpropionic acids as potent VLA-4 antagonists.
The discovery and SAR of 2,3-diphenylpropionic acid derivatives as highly...
3rd May, 2005
Central Research Laboratories, Kaken Pharmaceutical Co. Ltd, 14 Bioorg Med Chem Lett. 2005 Jan 3;15(1):217-20.
DOI Direct Link
General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide.
The general pharmacological effects of the hexapeptide KP-102...
17th February, 2005
Central Research Laboratories, Kaken Pharmaceutical Co., Ltd, Kyoto, Arzneimittelforschung. 2004;54(12):868-80.
Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide.
KP-102...
17th February, 2005
Department of Pharmacology, Central Research Laboratories, Kaken Arzneimittelforschung. 2004;54(12):857-67.
Reverse hydroxamate-based selective TACE inhibitors.
Reverse hydroxamate-based selective TACE inhibitors are described. They...
5th January, 2005
Kaken Pharmaceutical Co., Ltd, 14, Shinomiya, Minamikawara-cho, Kyoto, Bioorg Med Chem Lett. 2004 Jun 7;14(11):2897-900.
DOI Direct Link
Sibutramine induces potential-dependent exocytotic release but not carrier-mediated release of dopamine and 5-hydroxytryptamine.
In order to clarify the mechanism underlying the anti-obesity effects of...
24th September, 2004
Central Research Institute, Kaken Pharmaceutical Co. Ltd., 14 Shinomiya Eur J Pharmacol. 2004 Jan 26;484(2-3):209-15.
Paeciloxazine, a novel nematicidal antibiotic from Paecilomyces sp.
A novel nematicidal antibiotic, paeciloxazine has been isolated from the...
21st April, 2004
Research Laboratory Agrochemical & Animal Health Products Department, J Antibiot (Tokyo). 2004 Jan;57(1):24-8.

«Kaken Pharmaceutical Co Limited

This page contained an extended Kaken Pharmaceutical Co Limited research listing. Click here to return to the Kaken Pharmaceutical Co Limited main Biocorporate entry.

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.